← Leaderboards
Adrian Vincent Lee
Baylor College Of Medicine
$9,294,282
Attributed
$12,383,468
Total exposure
9
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.7M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$12,383,468 · 9
By mechanism
R01$9,462,329 · 5
P01$1,133,305 · 1
P50$1,028,650 · 1
S10$573,647 · 1
P30$185,537 · 1
Top collaborators
- Steffi Oesterreich11 shared
- George C. Tseng1 shared
Most similar at Baylor College Of Medicine
Same institution · by research overlap
- Steffi Oesterreich$10,632,097
- Powel H Brown$10,794,797
- Meghana V Trivedi$280,151
- Mary E Dickinson$26,271,179
- Mothaffar Fahed Rimawi$376,273
Others in their field
Top investigators on “Response”
- Lawrence Corey · Fred Hutchinson Cancer Center$677,505,141
- David Divins · Consortium For Ocean Leadership, Inc$609,772,544
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$532,027,174
- Barton F Haynes · Duke University$497,761,007
- Jeffrey P Krischer · University Of South Florida$397,532,270
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$342,310,423
Research focus
ResponseMalignant Breast NeoplasmTumorMalignant NeoplasmsCellsMolecularClinical TrialsGrowthXenograft ProcedureHistologicTranslatingPathway InteractionsGenesIn VitroIn VivoHormone TherapyResistanceMultidisciplinaryCell LineBioinformaticsMammary NeoplasmsTumor ProgressionPatient Derived Xenograft ModelFunding
Grant awards (43)
Single-cell congruence evaluation and selection of cancer models towards precision medicine$585,931
R01 · FY2025 · CA
Estrogen receptor fusions genes as drivers of endocrine resistance in breast cancer$579,181
R01 · FY2025 · CA · contact PI
Credentialing Models of Invasive Lobular Breast Cancer for Translational Research$527,799
R01 · FY2025 · CA
Estrogen receptor fusions genes as drivers of endocrine resistance in breast cancer$550,223
R01 · FY2024 · CA · contact PI
Credentialing Models of Invasive Lobular Breast Cancer for Translational Research$355,698
R01 · FY2024 · CA
Credentialing Models of Invasive Lobular Breast Cancer for Translational Research$570,252
R01 · FY2023 · CA
Estrogen receptor fusions genes as drivers of endocrine resistance in breast cancer$567,598
R01 · FY2023 · CA · contact PI
Developing and credentialing murine models of ILC$148,387
R01 · FY2023 · CA
Credentialing Models of Invasive Lobular Breast Cancer for Translational Research$568,084
R01 · FY2022 · CA
Estrogen receptor fusions genes as drivers of endocrine resistance in breast cancer$565,878
R01 · FY2022 · CA · contact PI
Estrogen receptor fusions genes as drivers of endocrine resistance in breast cancer$586,301
R01 · FY2021 · CA · contact PI
High-Throughput Computing for Genomics and Bioinformatics Research$573,647
S10 · FY2021 · OD · contact PI
Credentialing Models of Invasive Lobular Breast Cancer for Translational Research$573,041
R01 · FY2021 · CA
Breast and Ovarian Cancer Program (Project-007)$34,500
P30 · FY2019 · CA · contact PI
Breast and Ovarian Cancer Program (Project-007)$34,500
P30 · FY2018 · CA · contact PI
Breast and Ovarian Cancer Program (Project-007)$8,614
P30 · FY2018 · CA · contact PI
Breast and Ovarian Cancer Program (Project-007)$3,971
P30 · FY2018 · CA · contact PI
Breast and Ovarian Cancer Program (Project-007)$34,500
P30 · FY2017 · CA · contact PI
Breast and Ovarian Cancer Program (Project-007)$34,673
P30 · FY2016 · CA · contact PI
IRS-1 and -2 signaling in mammary development and cancer$291,393
R01 · FY2015 · CA · contact PI
Breast and Ovarian Cancer Program (Project-007)$34,779
P30 · FY2015 · CA · contact PI
IRS-1 and -2 signaling in mammary development and cancer$260,080
R01 · FY2014 · CA · contact PI
IRS-1 and -2 signaling in mammary development and cancer$1
R01 · FY2013 · CA · contact PI
IRS-1 and -2 signaling in mammary development and cancer$288,411
R01 · FY2012 · CA · contact PI
Targeting the IGF Pathway for Treatment of Breast Cancer$228,105
P50 · FY2012 · CA · contact PI
IRS-1 and -2 signaling in mammary development and cancer$288,411
R01 · FY2011 · CA · contact PI
Targeting the IGF Pathway for Treatment of Breast Cancer$234,309
P50 · FY2011 · CA · contact PI
IRS-1 and -2 signaling in mammary development and cancer$301,256
R01 · FY2010 · CA · contact PI
Targeting the IGF Pathway for Treatment of Breast Cancer$246,318
P50 · FY2010 · CA · contact PI
Targeting the IGF Pathway for Treatment of Breast Cancer$160,538
P50 · FY2009 · CA · contact PI
IGF-1 and its Cross-Talk with Estrogen During Breast Tumor Progression$298,184
P01 · FY2008 · CA · contact PI
Targeting the IGF Pathway for Treatment of Breast Cancer$159,380
P50 · FY2008 · CA · contact PI
IGF-1 and its Cross-Talk with Estrogen During Breast Tumor Progression$295,373
P01 · FY2007 · CA · contact PI
IRS1 and 2 Signaling in Mammary Development and Cancer$279,767
R01 · FY2006 · CA · contact PI
ER Co-Repressor Function of SAFB in Breast Cancer$261,595
R01 · FY2006 · CA · contact PI
IGF-1& its Cross-Talk with Estrogen in Breast Tumor Grow$185,259
P01 · FY2006 · CA · contact PI
IRS1 and 2 Signaling in Mammary Development and Cancer$394,217
R01 · FY2005 · CA
IGF-1&its Cross-Talk with Estrogen in Breast Tumor Grow$179,864
P01 · FY2005 · CA
IRS1 and 2 Signaling in Mammary Development and Cancer$266,217
R01 · FY2004 · CA
IGF-1&its Cross-Talk with Estrogen in Breast Tumor Grow$174,625
P01 · FY2004 · CA
IRS1 and 2 Signaling in Mammary Development and Cancer$120,174
R01 · FY2004 · CA
IRS1 and 2 Signaling in Mammary Development and Cancer$266,217
R01 · FY2003 · CA
IRS1 and 2 Signaling in Mammary Development and Cancer$266,217
R01 · FY2002 · CA